Analyzing 28209496 remdesivir Superclasses: 11173 - chemical compound 603741 - Prodrug 846227 - antiviral drug 578779 - pure substance 20026787 - chemical component 79529 - chemical substance 28732711 - physical substance 43460564 - chemical entity 1310239 - component 19478619 - metaclass 1454986 - physical system 4406616 - concrete object 58416391 - spatial entity 15989253 - part 223557 - physical object 30060700 - object of science 337060 - perceptible object 35120 - something 58778 - system 6671777 - structure 5127848 - class 488383 - object 58415929 - spatio-temporal entity 7184903 - abstract object 12187 - antibiotic 178859 - antimicrobial drug 40207875 - antiviral agent 50377176 - anti-infective agent 68541106 - antimicrobial agent 12140 - medication 409205 - xenobiotic 50379781 - therapeutic use 804539 - bactericide 8386 - drug 50377224 - pharmacologic action 1724915 - use 50377228 - chemical actions and uses 1150070 - change 1190554 - occurrence 16887380 - group 1914636 - activity 20937557 - series 26907166 - temporal entity 3249551 - process 3769299 - human behaviour 4026292 - action 451967 - intentional human action 61788060 - human activity 9332 - behavior 937228 - property Subclasses: Instances: Properties: label Plabel remdesivir description Pdescription chemical compound alias Palias GS-5734 alias Palias 2-ethylbutyl (2S)-2-({[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl}amino)propanoate page Ppage Remdesivir 0 0 0 231 CAS Registry Number e 1809249-37-3 661 ChemSpider ID e 58827832 665 KEGG ID e D11472 662 PubChem CID e 121304016 6099 clinical trial phase q 42824827 phase III clinical trial 366 use q 846227 antiviral drug 117 chemical structure v Remdesivir.svg 233 canonical SMILES s Nc3ncnn2c3ccc2C(C#N)(C1O)OC(C1O)CO[P]( 715 DrugBank ID e 14761 2017 isomeric SMILES s CCC(CC)COC( 274 chemical formula s C₂₇H₃₅N₆O₈P 234 InChI e 1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1 235 InChIKey e RWWYLEGWBNMMLJ-YSOARWBDSA-N 636 route of administration q 640448 intravenous infusion and defusion 2067 mass n 602.585 (28924752) 3345 RxNorm ID e 2284718 178 developer q 663596 Gilead Sciences 972 catalog q 90481889 CAS COVID-19 Anti-Viral Candidate Compounds 595 Guide to Pharmacology Ligand ID e 10715 5008 on focus list of Wikimedia project q 87748614 WikiProject COVID-19 1909 side effect q 1349821 hepatotoxicity : 5102 nature of statement q 28962312 often